{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:48:44Z","timestamp":1792586924971,"version":"4.5.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":110,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1053\/j.semnuclmed.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:50:40Z","timestamp":1777319440000},"page":"577-592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radiopharmaceuticals for imaging T-cells"],"prefix":"10.1053","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-5059","authenticated-orcid":false,"given":"Chiara","family":"Lauri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3809-0182","authenticated-orcid":false,"given":"Erik","family":"Aarntzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8081-0641","authenticated-orcid":false,"given":"Andor W.","family":"Glaudemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-0795","authenticated-orcid":false,"given":"Jelena","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-648X","authenticated-orcid":false,"given":"Alberto","family":"Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.001_bib0001","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3390\/jcm8050681","article-title":"Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology","volume":"8","author":"Signore","year":"2019","journal-title":"J Clin Med"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0002","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11307-011-0527-x","article-title":"99mTc-labeled Rituximab for Imaging B Lymphocyte Infiltration in Inflammatory Autoimmune Disease Patients","volume":"14","author":"Malviya","year":"2012","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.03.001_bib0003","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40336-013-0041-z","article-title":"Multiagent imaging of inflammation and infection with radionuclides","volume":"1","author":"Palestro","year":"2013","journal-title":"Clin Transl Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.001_bib0004","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood.V32.5.738.738","article-title":"Leukocyte labeling with 51-Chromium. I. Technic and results in normal subjects","volume":"32","author":"McMillan","year":"1968","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0005","first-page":"480","article-title":"Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. I. Soluble agents","volume":"17","author":"McAfee","year":"1976","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0006","first-page":"1014","article-title":"Indium-111-labeled autologous leukocytes in man","volume":"18","author":"Thakur","year":"1977","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0007","first-page":"487","article-title":"Kinetics and migration of indium-l 11 labelled lymphocytes in medical radionuclide imaging","volume":"1","author":"Goodwin","year":"1981","journal-title":"Int. In Atomic Energy Agency"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.03.001_bib0008","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-0609.1983.tb01505.x","article-title":"Kinetics of indium-111-labelled T lymphocytes in a patient with adult T-cell leukaemia","volume":"30","author":"Yamauchi","year":"1983","journal-title":"Scand J Haematol"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0009","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2337\/diab.31.5.463","article-title":"Trapping of peripheral blood lymphocytes in the pancreas of patients with acute onset insulin dependent diabetes mellitus","volume":"31","author":"Kaldany","year":"1982","journal-title":"Diabetes"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2265.1983.tb00749.x","article-title":"Tracking of indium-111-oxine labelled lymphocytes in autoimmune thyroid disease","volume":"19","author":"Pozzilli","year":"1983","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.03.001_bib0011","first-page":"1308","article-title":"Cell damage resulting from the labeling of rat lymphocytes and HeLa S3 cells with In-111 oxine","volume":"20","author":"Chisholm","year":"1979","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.03.001_bib0012","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0165-2478(83)90097-4","article-title":"Labelling of lymphocytes with indium 111 oxine: effect on cell surface phenotype and antibody-dependent cellular cytotoxicity","volume":"6","author":"Signore","year":"1983","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0013","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1053\/j.semnuclmed.2022.08.011","article-title":"Present status and future trends in molecular imaging of lymphocytes","volume":"53","author":"Lauri","year":"2023","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0014","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/j.transproceed.2004.09.085","article-title":"Preliminary results of [99mTc]OKT3 scintigraphy to evaluate acute rejection in renal transplants","volume":"36","author":"Martins","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1259\/bjr\/63780400","article-title":"Monitoring rheumatoid arthritis synovitis with 99m Tc-anti-CD3","volume":"81","author":"Martins","year":"2008","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0016","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/00006231-199410000-00008","article-title":"Imaging rheumatic joint diseases with anti-T lymphocyte antibody OKT-3","volume":"15","author":"Marcus","year":"1994","journal-title":"Nucl Med Commun"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.001_bib0017","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/rheumatology\/kep471","article-title":"Use of 99mTc-anti-CD3 scintigraphy in the differential diagnosis of rheumatic diseases","volume":"49","author":"Paiva Proen\u00e7a Lobo Lopes","year":"2010","journal-title":"Rheumatology"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0018","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2967\/jnumed.108.059485","article-title":"Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes","volume":"50","author":"Malviya","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193832","article-title":"Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors","volume":"13","author":"Beckford Vera","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0020","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2967\/jnumed.116.173930","article-title":"Quantitative CD3 PET imaging predicts tumor growth response to anti-CTLA-4 therapy","volume":"57","author":"Larimer","year":"2016","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.001_bib0021","first-page":"1314","article-title":"Using immuno-PET imaging to monitor kinetics of T cell-mediated inflammation and treatment efficiency in a humanized mouse model for GvHD","volume":"47","author":"Pektor","year":"2020","journal-title":"EJNMMI"},{"issue":"20","key":"10.1053\/j.semnuclmed.2026.03.001_bib0022","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1158\/1078-0432.CCR-18-0786","article-title":"Molecular imaging of radiolabeled bispecific T-cell engager 89Zr-AMG211 targeting CEA-positive tumors","volume":"24","author":"Waaijer","year":"2018","journal-title":"Clinical Cancer Research"},{"issue":"17","key":"10.1053\/j.semnuclmed.2026.03.001_bib0023","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1158\/1078-0432.CCR-15-2622","article-title":"Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing","volume":"22","author":"Lehmann","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.03.001_bib0024","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1158\/1078-0432.CCR-18-2918","article-title":"89Zr-labeled bispecific T-cell engager AMG 211 PET shows AMG 211 accumulation in CD3-rich tissues and clear, heterogeneous tumor uptake","volume":"25","author":"Moek","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nucmedbio.2012.08.004","article-title":"PET imaging with 89Zr: from radiochemistry to the clinic","volume":"40","author":"Deri","year":"2013","journal-title":"Nuclear medicine and biology"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.03.001_bib0026","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1084\/jem.184.6.2439","article-title":"CD8\u03b2; increases CD8 coreceptor function and participation in TCR\u2013ligand binding","volume":"184","author":"Renard","year":"1996","journal-title":"The Journal of experimental medicine"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0027","article-title":"The role of CD8 PET imaging in guiding cancer immunotherapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0028","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13058-024-01844-3","article-title":"Evaluating the immunologically \u201ccold\u201d tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4+ and CD8+ T cells in breast cancer mouse models","volume":"26","author":"Lu","year":"2024","journal-title":"Breast Cancer Research"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.03.001_bib0029","first-page":"287","article-title":"Preclinical development of ZED8, an (89)Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy","volume":"50","author":"Ogasawara","year":"2022","journal-title":"EJNMMI"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.03.001_bib0030","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/2326-6066.CIR-21-0405","article-title":"Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054","volume":"10","author":"Tavar\u00e9","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0031","doi-asserted-by":"crossref","unstructured":"Maresca KP, Chen J, Mathur D, Giddabasappa A, Root A, Narula J, King L, Schaer D, Golas J, Kobylarz K, Rosfjord E, Keliher E, Chen L, Ram S, Pickering EH, Hardwick JS, Rejto PA, Hussein A, Ilovich O, Staton K, Wilson I, McCarthy TJ. Preclinical Evaluation of (89)Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy. Mol Imaging Biol 23:941-951. doi: 10.1007\/s11307-021-01621-0.","DOI":"10.1007\/s11307-021-01621-0"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0032","first-page":"193","article-title":"Specific imaging of CD8\u2009+\u2009T-Cell dynamics with a nanobody radiotracer against human CD8\u03b2;","volume":"52","author":"De Groof","year":"2024","journal-title":"EJNMMI"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.03.001_bib0033","first-page":"679","article-title":"Development of an 18F-labeled anti-human CD8 VHH for same-day immunoPET imaging","volume":"50","author":"Sriraman","year":"2022","journal-title":"EJNMMI"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0034","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12951-021-00785-9","article-title":"ImmunoPET imaging of human CD8+ T cells with novel 68Ga-labeled nanobody companion diagnostic agents","volume":"19","author":"Zhao","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0035","article-title":"Preliminary evidence of localizing CD8+ T-cell responses in COVID-19 patients with PET imaging","volume":"11","author":"Koenen","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"41","key":"10.1053\/j.semnuclmed.2026.03.001_bib0036","doi-asserted-by":"crossref","first-page":"eadh7968","DOI":"10.1126\/sciadv.adh7968","article-title":"First-in-human immunoPET imaging of COVID-19 convalescent patients using dynamic total-body PET and a CD8-targeted minibody","volume":"9","author":"Omidvari","year":"2023","journal-title":"Sci Adv"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.03.001_bib0037","doi-asserted-by":"crossref","first-page":"e1158","DOI":"10.1212\/WNL.0000000000207596","article-title":"Imaging With PET\/CT of Diffuse CD8 T-Cell Infiltration of Skeletal Muscle in Patients With Inclusion Body Myositis","volume":"101","author":"Quinn","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.001_bib0038","first-page":"720","article-title":"Pandit-Taskar N. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody","volume":"63","author":"Farwell","year":"2021","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.03.001_bib0039","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41591-022-02084-8","article-title":"Whole-body CD8(+) T cell visualization before and during cancer immunotherapy: a phase 1\/2 trial","volume":"28","author":"Kist de Ruijter","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799910","article-title":"Single-Domain Antibodies for Targeting, Detection, and In Vivo Imaging of Human CD4+ Cells","volume":"12","author":"Traenkle","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.03.001_bib0041","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/1535-7163.MCT-21-0888","article-title":"Noninvasive Imaging of CD4+ T Cells in Humanized Mice","volume":"21","author":"Nagle","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"26","key":"10.1053\/j.semnuclmed.2026.03.001_bib0042","doi-asserted-by":"crossref","first-page":"eadw1924","DOI":"10.1126\/sciadv.adw1924","article-title":"PET-based immunomapping of intratumoral CD4+ cells to monitor acquired resistance to checkpoint inhibitors","volume":"11","author":"Pezzana","year":"2025","journal-title":"Sci Adv"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0043","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2967\/jnumed.121.261926","article-title":"de Langen AJ. Study of (89)Zr-Pembrolizumab PET\/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer","volume":"63","author":"Niemeijer","year":"2022","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0044","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.annonc.2021.10.213","article-title":"(89)Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer","volume":"33","author":"Kok","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0045","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0046","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.124.268068","article-title":"Preclinical Evaluation and Pilot Clinical Study of CD137 PET Radiotracer for Noninvasive Monitoring Early Responses of Immunotherapy","volume":"66","author":"Cheng","year":"2025","journal-title":"J Nucl Med"},{"issue":"13","key":"10.1053\/j.semnuclmed.2026.03.001_bib0047","first-page":"4369","article-title":"Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy","volume":"48","author":"van de Donk","year":"2021","journal-title":"EJNMMI"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0048","first-page":"544","article-title":"[68Ga]Ga-interleukin-2 for imaging activated T-lymphocytes: Biochemical characterization and phase I study in normal subjects","volume":"53","author":"Signore","year":"2025","journal-title":"EJNMMI"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0049","doi-asserted-by":"crossref","first-page":"8791","DOI":"10.1038\/s41467-024-53197-2","article-title":"(68)Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1\/2 clinical trial","volume":"15","author":"Shen","year":"2024","journal-title":"Nat Commun"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0050","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2967\/jnumed.124.267529","article-title":"Granzyme B PET\/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer","volume":"65","author":"Liu","year":"2024","journal-title":"J Nucl Med"},{"issue":"7858","key":"10.1053\/j.semnuclmed.2026.03.001_bib0051","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","article-title":"Cell-programmed nutrient partitioning in the tumour microenvironment","volume":"593","author":"Reinfeld","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.03.001_bib0052","first-page":"510","article-title":"EANM\/SNMMI guideline\/procedure standard for [(18)F]FDG hybrid PET use in infection and inflammation in adults v2.0","volume":"52","author":"Abikhzer","year":"2024","journal-title":"EJNMMI"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.03.001_bib0053","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","article-title":"Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET\/CT","volume":"44","author":"Nobashi","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"45","key":"10.1053\/j.semnuclmed.2026.03.001_bib0054","doi-asserted-by":"crossref","first-page":"18396","DOI":"10.1073\/pnas.1113045108","article-title":"Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3\u2032;-fluoro-3\u2032-deoxy-thymidine ([18F]FLT) PET imaging","volume":"108","author":"Aarntzen","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"38","key":"10.1053\/j.semnuclmed.2026.03.001_bib0055","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.1073\/pnas.1706689114","article-title":"Detection of immune responses after immunotherapy in glioblastoma using PET and MRI","volume":"114","author":"Antonios","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.03.001_bib0056","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1158\/0008-5472.CAN-16-2953","article-title":"A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant","volume":"77","author":"Ronald","year":"2017","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0057","doi-asserted-by":"crossref","DOI":"10.1177\/1536012117712638","article-title":"In Vivo PET Imaging of the Activated Immune Environment in a Small Animal Model of Inflammatory Arthritis","volume":"16","author":"Franc","year":"2017","journal-title":"Mol Imaging"},{"issue":"13","key":"10.1053\/j.semnuclmed.2026.03.001_bib0058","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1158\/0008-5472.CAN-19-0267","article-title":"Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy","volume":"79","author":"Levi","year":"2019","journal-title":"Cancer Res"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.03.001_bib0059","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2967\/jnumed.120.249078","article-title":"18F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy","volume":"62","author":"Levi","year":"2021","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2967\/jnumed.120.259325","article-title":"Longitudinal Imaging of T Cells and Inflammatory Demyelination in a Preclinical Model of Multiple Sclerosis Using 18F-FAraG PET and MRI","volume":"63","author":"Guglielmetti","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0061","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3667417","article-title":"Biodistribution of a Mitochondrial Metabolic Tracer, [(18)F]F-AraG, in Healthy Volunteers","volume":"2022","author":"Levi","year":"2022","journal-title":"Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0062","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s42003-024-06494-x","article-title":"[18F]F-AraG imaging reveals association between neuroinflammation and brown- and bone marrow adipose tissue","volume":"7","author":"Levi","year":"2024","journal-title":"Commun Biol"},{"issue":"754","key":"10.1053\/j.semnuclmed.2026.03.001_bib0063","doi-asserted-by":"crossref","first-page":"eadk3295","DOI":"10.1126\/scitranslmed.adk3295","article-title":"Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection","volume":"16","author":"Peluso","year":"2024","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.001_bib0064","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11307-024-01932-y","article-title":"A Feasibility Study of [18F]F-AraG Positron Emission Tomography (PET) for Cardiac Imaging-Myocardial Viability in Ischemia-Reperfusion Injury Model","volume":"26","author":"Shrestha","year":"2024","journal-title":"Mol Imaging Bio"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.03.001_bib0065","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2967\/jnumed.123.267003","article-title":"Total-Body Dynamic Imaging and Kinetic Modeling of [18F]F-AraG in Healthy Individuals and a Non-Small Cell Lung Cancer Patient Undergoing Anti-PD-1 Immunotherapy","volume":"65","author":"Omidvari","year":"2024","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.03.001_bib0066","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00259-024-06931-3","article-title":"Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer","volume":"52","author":"Wijngaarden","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.03.001_bib0067","first-page":"1869","article-title":"[(18)F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy","volume":"65","author":"Levi","year":"2024","journal-title":"J Nucl Med"},{"issue":"13","key":"10.1053\/j.semnuclmed.2026.03.001_bib0068","article-title":"Mitochondrial Imaging Detects Early Cardiac Responses to Cancer Immunotherapy","volume":"10","author":"Chae","year":"2025","journal-title":"medRxiv"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.03.001_bib0069","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.125.269799","article-title":"Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation of 89Zr-Ivuxolimab, a Human OX40 PET Tracer","volume":"66","author":"Kalita","year":"2025","journal-title":"J Nucl Med"},{"issue":"16","key":"10.1053\/j.semnuclmed.2026.03.001_bib0070","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1182\/bloodadvances.2022007403","article-title":"ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD","volume":"6","author":"Xiao","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.03.001_bib0071","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/2767-9764.CRC-22-0434","article-title":"Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma","volume":"3","author":"Nisnboym","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0072","first-page":"242","article-title":"123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease","volume":"41","author":"Signore","year":"2000","journal-title":"JNM"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0073","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/PL00006657","article-title":"Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet","volume":"27","author":"Signore","year":"2000","journal-title":"Eur J Nucl Med"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0074","first-page":"139","article-title":"123-interleukin-2 scintigraphy: a new approach to assess disease activity in autoimmunity","volume":"9","author":"Signore","year":"1996","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0075","first-page":"355","article-title":"In vivo labelling of activated T lymphocytes by iv injection of 123I-IL2 for detection of insulitis in type 1 diabetes","volume":"1","author":"Signore","year":"1990","journal-title":"Progress in Clinical and Biological Research"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.03.001_bib0076","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1530\/eje.0.1310431","article-title":"New approach for in vivo detection of insulitis in type I diabetes: activated lymphocyte targeting with 123I-labelled interleukin 2","volume":"131","author":"Signore","year":"1994","journal-title":"European journal of endocrinology"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.03.001_bib0077","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00006231-200303000-00011","article-title":"123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases","volume":"24","author":"Signore","year":"2003","journal-title":"Nuclear Medicine Communications"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.03.001_bib0078","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0090-9556(25)06727-3","article-title":"A comparison of mass balance, pharmacokinetics and disposition of [14C (U)]-and [125I] recombinant human interleukin-2 in cynomolgus monkeys","volume":"23","author":"Nadeau","year":"1995","journal-title":"Drug metabolism and disposition"},{"issue":"03","key":"10.1053\/j.semnuclmed.2026.03.001_bib0079","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-0029-1210654","article-title":"Labelling of interleukin-2 (IL-2) with 123-iodine with retention of its capacity to bind to activated lymphocytes","volume":"89","author":"Signore","year":"1987","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0080","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(87)92925-4","article-title":"Detection of activated lymphocytes in endocrine pancreas of BB\/W rats by injection of 123I-interleukin-2: an early sign of type 1 diabetes","volume":"330","author":"Signore","year":"1987","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.03.001_bib0081","first-page":"352","article-title":"Iodine-123-interleukin-2 scintigraphy in metastatic hypernephroma: a pilot study","volume":"51","author":"Renard","year":"2007","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.03.001_bib0082","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00259-007-0609-9","article-title":"(123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma","volume":"35","author":"Loose","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0083","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0966-3274(93)90058-G","article-title":"Analysis of activated T cell infiltrates in rat renal allografts by gamma camera imaging after injection of 123iodine-interleukin 2","volume":"1","author":"Abbs","year":"1993","journal-title":"Transplant Immunology"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.03.001_bib0084","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00006231-199213100-00003","article-title":"A radiopharmaceutical for imaging areas of lymphocytic infiltration: 123I-interleukin-2. Labelling procedure and animal studies","volume":"13","author":"Signore","year":"1992","journal-title":"Nuclear medicine communications"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.03.001_bib0085","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0969-8051(97)00021-8","article-title":"The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases","volume":"24","author":"Chianelli","year":"1997","journal-title":"Nucl Med Biol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.001_bib0086","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11307-009-0285-1","article-title":"Synthesis and optimization of the labeling procedure of 99mTc-HYNIC-interleukin-2 for in vivo imaging of activated T lymphocytes","volume":"12","author":"D'Alessandria","year":"2009","journal-title":"Mol Imaging Biol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.03.001_bib0087","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.nucmedbio.2010.04.013","article-title":"Investigation of 99mTc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide","volume":"37","author":"Karczmarczyk","year":"2010","journal-title":"Nucl Med Biol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.03.001_bib0088","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2337\/dc14-0580","article-title":"Action LADA Group. Detection of insulitis by pancreatic scintigraphy with 99mTc-labeled IL-2 and MRI in patients with LADA (Action LADA 10)","volume":"38","author":"Signore","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.03.001_bib0089","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/dmrr.767","article-title":"IMDIAB study group. Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy","volume":"24","author":"Chianelli","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.03.001_bib0090","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00259-002-1069-x","article-title":"99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease","volume":"30","author":"Annovazzi","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.03.001_bib0091","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1007\/s00259-008-0837-7","article-title":"99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study","volume":"35","author":"Chianelli","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.03.001_bib0092","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00259-005-1899-4","article-title":"99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques","volume":"33","author":"Annovazzi","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.03.001_bib0093","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1007\/s00259-014-2764-0","article-title":"In vivo and in vitro evidence that 99mTc-HYNIC-interleukin-2 is able to detect T lymphocytes in vulnerable atherosclerotic plaques of the carotid artery","volume":"41","author":"Glaudemans","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.03.001_bib0094","first-page":"1225","article-title":"Diagnosis and followup of Takayasu's arteritis by scintigraphy with radiolabelled interleukin 2","volume":"31","author":"Lucia","year":"2004","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.03.001_bib0095","first-page":"1647","article-title":"99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study","volume":"45","author":"Signore","year":"2004","journal-title":"Journal of Nuclear Medicine"},{"issue":"54","key":"10.1053\/j.semnuclmed.2026.03.001_bib0096","doi-asserted-by":"crossref","first-page":"30268","DOI":"10.18632\/oncotarget.25666","article-title":"Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study","volume":"9","author":"Markovic","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.001_bib0097","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2967\/jnumed.111.091306","article-title":"N-(4-18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes","volume":"53","author":"Di Gialleonardo","year":"2012","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.03.001_bib0098","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00259-012-2176-y","article-title":"Pharmacokinetic modelling of N-(4-[18F] fluorobenzoyl) interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation","volume":"39","author":"Di Gialleonardo","year":"2012","journal-title":"European journal of nuclear medicine and molecular imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.03.001_bib0099","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1021\/acs.jmedchem.4c00154","article-title":"Arginine-Selective Bioconjugation Reagent for Effective 18F-labeling of Native Proteins","volume":"67","author":"Sadasivam","year":"2024","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117617","article-title":"Novel [18F]FPG-interleukin-2 conjugate for monitoring immune checkpoint therapy with positron emission tomography","volume":"180","author":"Sadasivam","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.03.001_bib0101","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1039\/D1RE00117E","article-title":"Radiolabelling an 18F biologic via facile IEDDA \u201cclick\u201d chemistry on the GE FASTLab\u2122 platform","volume":"6","author":"Allott","year":"2021","journal-title":"React Chem Eng"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s41181-019-0062-7","article-title":"Clinical-grade N-(4-[18F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans","volume":"4","author":"Van der Veen","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.03.001_bib0103","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.18632\/oncotarget.23852","article-title":"Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study","volume":"9","author":"Hartimath","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.03.001_bib0104","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2967\/jnumed.119.238782","article-title":"Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice","volume":"61","author":"van der Veen","year":"2020","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.03.001_bib0105","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3390\/molecules26061728","article-title":"An Improved Synthesis of N-(4-[18F]Fluorobenzoyl)-Interleukin-2 for the Preclinical PET Imaging of Tumour-Infiltrating T-cells in CT26 and MC38 Colon Cancer Models","volume":"26","author":"Khanapur","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.001_bib0106","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1248014","article-title":"Noninvasive monitoring of cancer therapy induced activated T cells using [18F]FB-IL-2 PET imaging","volume":"6","author":"Hartimath","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0107","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.3390\/jcm14165658","article-title":"Validation of a Ready-to-Use Lyophilized Kit for Labeling IL2 with 68Ga: A New Avenue for Imaging Activated T-lymphocytes in Tumor Microenvironment","volume":"14","author":"Lauri","year":"2025","journal-title":"J. Clin. Med."},{"issue":"S12","key":"10.1053\/j.semnuclmed.2026.03.001_bib0108","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2650::AID-CNCR41>3.0.CO;2-8","article-title":"Biodistribution of iodine-125 labeled monoclonal antibody\/Interleukin-2 immunoconjugate in athymic mice bearing human tumor xenografts","volume":"80","author":"Nakamura","year":"1997","journal-title":"Cancer: Interdisciplinary International Journal of the American Cancer Society"},{"key":"10.1053\/j.semnuclmed.2026.03.001_bib0109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1017132","article-title":"Cysteine-specific 89Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-\u03b1 on T cell lymphomas","volume":"13","author":"Lee","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.03.001_bib0110","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/bc980129m","article-title":"Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc","volume":"10","author":"Kim","year":"1999","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.03.001_bib0111","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/bc970032k","article-title":"Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment","volume":"8","author":"Wu","year":"1997","journal-title":"Bioconjugate chemistry"},{"issue":"22","key":"10.1053\/j.semnuclmed.2026.03.001_bib0112","first-page":"5323","article-title":"Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts","volume":"55","author":"Choi","year":"1995","journal-title":"Cancer Res"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.03.001_bib0113","first-page":"1955","article-title":"Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG","volume":"57","author":"Kobayashi","year":"1997","journal-title":"Cancer Res"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.03.001_bib0114","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1349-7006.1998.tb00582.x","article-title":"Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen","volume":"89","author":"Kobayashi","year":"1998","journal-title":"Jpn J Cancer Res"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.03.001_bib0115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00007890-198909000-00002","article-title":"Biodistribution of an anti-interleukin 2 receptor monoclonal antibody in rat recipients of a heart allograft, and its use as a rejection marker in gamma scintigraphy","volume":"48","author":"Thedrez","year":"1989","journal-title":"Transplantation"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.03.001_bib0116","first-page":"294","article-title":"Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment","volume":"38","author":"Yoo","year":"1997","journal-title":"Journal of Nuclear Medicine"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.001_bib0117","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/00007890-199011000-00005","article-title":"Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation","volume":"50","author":"Cooper","year":"1990","journal-title":"Transplantation"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.03.001_bib0118","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/00007890-199212000-00004","article-title":"Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colony-stimulating factor","volume":"54","author":"Gl","year":"1992","journal-title":"Transplantation"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.03.001_bib0119","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","article-title":"Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac","volume":"86","author":"Waldmann","year":"1995","journal-title":"Blood"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299826000504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299826000504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:30:49Z","timestamp":1792585849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299826000504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0001299826000504"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.03.001","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiopharmaceuticals for imaging T-cells","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}